Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR). Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - Neuro-Onc - NCCTG-N0776
Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib Lafky, J. M. , Bot, B. M. , Morlan, B. W. , Anderson, S. K. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - GI - N054C